On the public citation graph

Ribociclib Induced Liver Injury in a Patient with Metastatic Breast Cancer, a Case Report

https://doi.org/10.2139/ssrn.4758645
0 signed · 9 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1007/s11912-019-0769-3openalex-extracted
CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions
inferredcites →https://doi.org/10.1016/j.annonc.2020.09.010openalex-extracted
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
inferredcites →https://doi.org/10.1016/j.breast.2020.10.007openalex-extracted
Safety and efficacy of cyclin-dependent kinase inhibitor rechallenge following ribociclib-induced limiting hypertransaminasemia
inferredcites →https://doi.org/10.1056/nejmoa1607303openalex-extracted
Palbociclib and Letrozole in Advanced Breast Cancer
inferredcites →https://doi.org/10.1080/0284186x.2020.1853228openalex-extracted
Hepatotoxicity associated with ribociclib among breast cancer patients
inferredcites →https://doi.org/10.1093/annonc/mdy155openalex-extracted
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
inferredcites →https://doi.org/10.1097/cad.0000000000000845openalex-extracted
Palbociclib safety and efficacy beyond Ribociclib-induced liver toxicity in metastatic hormone-receptors positive breast cancer patient
inferredcites →https://doi.org/10.1200/jco.2017.75.6155openalex-extracted
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
inferredcites →https://doi.org/10.3389/fphar.2019.01235openalex-extracted
Strategies for Early Prediction and Timely Recognition of Drug-Induced Liver Injury: The Case of Cyclin-Dependent Kinase 4/6 Inhibitors
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.